Evidence map›Paper›PMID 30315512›Full record

ReviewPharmacoEconomics2019

The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence.

Richard Perry, George Braileanu, Thomas Palmer, Paul Stevens

Open access · hybridAbstract readReview
In one paragraph

Review in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 6 pooled it
34.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 6 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Non-invasive positive pressure ventilation for acute asthma in children.The Cochrane database of systematic reviews · 2024
    Pooled it
  6. Pulmonary Health Effects of Indoor Volatile Organic Compounds-A Meta-Analysis.International journal of environmental research and public health · 2021
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Timing of High-Risk Asthma Specialist Enrollment and Severe Asthma Exacerbations in Children.The journal of allergy and clinical immunology. In practice · 2026
    Article
  11. Observational
  12. Caregiver Empowerment of Children With Asthma: A Literature Review.Journal for specialists in pediatric nursing : JSPN · 2026
    Review
  13. Observational
  14. Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma.The journal of allergy and clinical immunology. Global · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Richard PerryAdelphi Values, Manchester, UK.
George BraileanuAdelphi Values, Manchester, UK.
Thomas PalmerAdelphi Values, Manchester, UK.
Paul StevensOMRON Healthcare Europe B.V., Hoofddorp, The Netherlands. paul.stevens@eu.omron.com.
Adelphi Group (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a chronic respiratory disease that is widespread throughout the US population and disproportionately affects children. This literature review aimed to identify recent information regarding the economic burden of pediatric asthma in the US. MEDLINE, EMBASE, Econlit, and PsycINFO databases and gray literature sources were searched from January 2012 to January 2018 to capture relevant publications. Publications reporting on healthcare resource utilization and/or healthcare costs of pediatric asthma were included (n = 8). Total direct costs of pediatric asthma were US$5.92 billion in 2013. Average annual costs per child ranged from US$3076 to US$13612. Across studies, pharmacy (US$1027-2120), inpatient (US$337-2016) and outpatient (US$1049-8039) costs were the primary contributors to healthcare costs. Inpatient and emergency department (ED) visits exerted a high economic burden. For instance, the national annual cost of asthma-related hospitalizations was estimated at US$1.59 billion in 2009, while estimates of costs-per-hospitalization (2010) and charges-per-discharge (2009) were US$3600 and US$8406, respectively. The total cost of ED visits to Medicaid was estimated at US$272 million in 2010. In a mixed-insurance population, ED cost estimates ranged from US$152 to US$172 annually per patient. Invariably, costs for children with asthma were significantly greater than for children without. Pediatric asthma imposes a significant economic burden to the US healthcare system. Children with asthma have significantly higher healthcare resource utilization and costs than children without asthma.

Indexed as

Cost of IllnessAsthmaChildEmergency Service, HospitalHealth Care CostsHospitalizationHumansUnited States

Identifiers

PMID30315512
PMCPMC6386052
OpenAlexW2896328421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.